Bioalmanac
Tirzepatide
GIP/GLP-1 dual agonist · LY3298176
A once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C and protected from light. Keep the powder dry until you are ready to use it.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze. Discard if cloudy or discoloured.
- Long-term, frozen
- Unopened lyophilised powder is stable at −20 °C or colder.
Reconstitution — 10 mg vial, 2500 mcg dose
On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.
| Water added | Concentration | Volume to draw | Units | Doses per vial |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.25 mL | 25 units | 4 |
| 2 mL | 5 mg/mL | 0.5 mL | 50 units | 4 |
| 3 mL | 3.333 mg/mL | 0.75 mL | 75 units | 4 |
| 5 mL | 2 mg/mL | — | Exceeds a 1 mL barrel | — |
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Trial escalation, weeks 1–4 | 2500 mcg | Once weekly | Clinical trial |
| Trial escalation, thereafter | 5000–12500 mcg | Once weekly, raised by 2.5 mg every four weeks | Clinical trial |
| Trial maintenance doses | 5000–15000 mcg | Once weekly | Clinical trial |
When to stop
- Severe, persistent abdominal pain radiating to the back, with or without vomiting. Seek urgent medical care.
- Persistent vomiting or inability to keep fluids down.
- Upper right abdominal pain, fever, or yellowing of the skin or eyes.
- A neck lump, hoarseness, or difficulty swallowing.
- Any allergic response: rash, hives, facial swelling, or difficulty breathing. Seek urgent care.
- If you become pregnant or are planning to.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.